Geode Capital Management
CRVS icon

Geode Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Geode Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.1M Buy
1,712,741
+239,715
+16% +$3.83M ﹤0.01% 1875
2025
Q4 		$11.3M Buy
1,473,026
+16,498
+1% +$130K ﹤0.01% 2353
2025
Q3 		$10.7M Buy
1,456,528
+94,788
+7% +$485K ﹤0.01% 2378
2025
Q2 		$5.45M Buy
1,361,740
+771,454
+131% +$2.81M ﹤0.01% 2683
2025
Q1 		$1.88M Buy
590,286
+23,423
+4% +$110K ﹤0.01% 3059
2024
Q4 		$3.03M Buy
566,863
+3,854
+0.7% +$28.8K ﹤0.01% 2978
2024
Q3 		$2.97M Buy
563,009
+102,869
+22% +$369K ﹤0.01% 3001
2024
Q2 		$838K Buy
460,140
+88,377
+24% +$165K ﹤0.01% 3377
2024
Q1 		$662K Buy
371,763
+11,383
+3% +$23.8K ﹤0.01% 3517
2023
Q4 		$634K Hold
360,380
– – ﹤0.01% 3525
2023
Q3 		$526K Buy
360,380
+18,301
+5% +$38.7K ﹤0.01% 3586
2023
Q2 		$783K Buy
342,079
+44,279
+15% +$92K ﹤0.01% 3450
2023
Q1 		$271K Hold
297,800
– – ﹤0.01% 3903
2022
Q4 		$253K Sell
297,800
-660
-0.2% -$584 ﹤0.01% 3966
2022
Q3 		$244K Hold
298,460
– – ﹤0.01% 4088
2022
Q2 		$295K Hold
298,460
– – ﹤0.01% 4036
2022
Q1 		$489K Buy
298,460
+13,586
+5% +$24.9K ﹤0.01% 3943
2021
Q4 		$686K Buy
284,874
+74,631
+35% +$289K ﹤0.01% 3884
2021
Q3 		$1.02M Buy
210,243
+20,702
+11% +$61.3K ﹤0.01% 3663
2021
Q2 		$506K Buy
189,541
+40,707
+27% +$112K ﹤0.01% 3940
2021
Q1 		$458K Buy
148,834
+38,174
+34% +$138K ﹤0.01% 3848
2020
Q4 		$393K Sell
110,660
-888
-0.8% -$3.58K ﹤0.01% 3671
2020
Q3 		$447K Sell
111,548
-32,814
-23% -$131K ﹤0.01% 3458
2020
Q2 		$392K Buy
144,362
+5,446
+4% +$16.1K ﹤0.01% 3455
2020
Q1 		$293K Buy
138,916
+1,361
+1% +$5.53K ﹤0.01% 3436
2019
Q4 		$748K Buy
137,555
+8,198
+6% +$28.7K ﹤0.01% 3373
2019
Q3 		$389K Buy
129,357
+14,563
+13% +$61.1K ﹤0.01% 3557
2019
Q2 		$429K Sell
114,794
-48,097
-30% -$188K ﹤0.01% 3519
2019
Q1 		$654K Buy
162,891
+10,530
+7% +$44.4K ﹤0.01% 3326
2018
Q4 		$559K Buy
152,361
+24,322
+19% +$166K ﹤0.01% 3333
2018
Q3 		$1.1M Buy
128,039
+4,686
+4% +$46.9K ﹤0.01% 3182
2018
Q2 		$1.35M Buy
123,353
+47,391
+62% +$529K ﹤0.01% 3057
2018
Q1 		$875K Buy
75,962
+1,963
+3% +$18.6K ﹤0.01% 3185
2017
Q4 		$766K Buy
73,999
+626
+0.9% +$8.02K ﹤0.01% 3204
2017
Q3 		$1.17M Buy
73,373
+4,599
+7% +$63.6K ﹤0.01% 3054
2017
Q2 		$832K Buy
68,774
+28,224
+70% +$301K ﹤0.01% 3174
2017
Q1 		$842K Buy
40,550
+2,570
+7% +$40.3K ﹤0.01% 3104
2016
Q4 		$543K Buy
37,980
+1,095
+3% +$16.7K ﹤0.01% 3237
2016
Q3 		$606K Buy
+36,885
New +$532K ﹤0.01% 3175

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management's CRVS Position: Q1 2026 in Review

Geode Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 16% in Q1 2026, buying an estimated $3.83M and bringing the position to 1,712,741 shares worth $25.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Geode Capital Management first reported a position in CRVS in Q3 2016 and has held it in 39 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Geode Capital Management held 1,712,741 shares of Corvus Pharmaceuticals worth $25.1M as of Q1 2026.
  • Geode Capital Management bought 239,715 Corvus Pharmaceuticals shares in Q1 2026, an estimated $3.83M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1875 holding.
  • Geode Capital Management first reported a position in Corvus Pharmaceuticals in Q3 2016 and has held it in 39 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.